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the analysis was restricted to patients who had received
≥4 prescriptions in the 6 months prior to their ﬁrst lan-
soprazole 15mg prescription (25%: 31/122). Amongst
those patients with a speciﬁc diagnosis of GORD/RO,
37% (15/41) switched to a higher dose PPI within 6
months. Around half (52%; 16/31) of patients who
returned to a higher dose had no speciﬁc reason recorded
(16/31). However the most commonly recorded reason
for failing on lansoprazole 15mg was inadequate control
of symptoms (35%; 11/31). CONCLUSION: The pro-
portion of patients changed from standard or high dose
PPI to lansoprazole 15mg who required an increase in
PPI therapy within 6 months was higher than that re-
ported for patients treated with esomeprazole 20mg.
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OBJECTIVE: The recommended treatment for Heli-
cobacter pylori eradication in the UK is a proton pump
inhibitor (PPI) in combination with amoxicillin 1g and
clarithromycin 500mg all twice daily for 7 days. The aim
of this analysis was to compare the efﬁcacies of the rec-
ommended PPI-based triple therapies for the eradication
of H. pylori using omeprazole-based triple therapy as a
common comparator. METHODS: The PPIs licensed in
the UK for twice daily triple therapy are esomeprazole 
20mg (EAC), lansoprazole 30mg (LAC), omeprazole 
20mg (OAC), pantoprazole 40mg (PAC), and rabepra-
zole 20mg (RAC). A meta-analysis of randomised con-
trolled trials comparing a 7-day regimen of PPI-based
triple therapies was conducted using omeprazole-based
triple therapy as a common comparator. Data on eradi-
cation rates were extracted and re-analysed, where
required, to provide “intention-to-treat” results. The
primary method of calculating the summary effect esti-
mates used a Fixed Effects model. A chi-squared test was
used to assess heterogeneity for each comparison. A sec-
ondary analysis comparing 7-day regimens of PPI plus
any dose of amoxycillin and clarithromycin was con-
ducted to test the robustness of the results. RESULTS:
The alternative strategies, compared with OAC, provided
the following results—EAC (Relative Risk 1.01; 95%
Conﬁdence Interval: 0.95 to 1.08), LAC (RR 1.05; 95%
CI: 0.94 to 1.17), PAC (RR 0.92; 95% CI: 0.80 to 1.06).
No trials comparing rabeprazole with omeprazole using
UK recommended triple therapy were found. Signiﬁcant
heterogeneity was detected in the LAC comparison with
OAC and so these results should be treated with caution.
The secondary analysis conﬁrmed that there was no sig-
niﬁcant difference in the four alternative strategies 
compared to OAC. CONCLUSIONS: No PPI-based
triple therapy was found to be signiﬁcantly more efﬁca-
cious than omeprazole-based triple therapy. However,
esomeprazole 20mg is the only PPI licensed in the UK for
triple therapy that would be considered a low dose.
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OBJECTIVE: Evidence-based techniques were applied to
clinical trial data of esomeprazole for maintaining healed
erosive esophagitis (EE) to provide a practical, quantita-
tive analysis of its efﬁcacy relative to lansoprazole.
METHODS: Patients with a history of heartburn and EE,
Los Angeles Grade A–D at baseline, received esomepra-
zole 40mg once daily for up to 8 weeks for healing. Those
with healed EE were randomized to receive once daily
esomeprazole 20mg (n = 615) or lansoprazole 15mg 
(n = 609) for up to 6 months. For this retrospective analy-
sis, the number needed to treat (NNT), the reciprocal of
the absolute risk reduction (ARR), was calculated at 6
months for all patients and for subgroups with mild
disease (LA Grade A or B) and severe disease (LA Grade
C or D). RESULTS: In this evidence-based analysis, it 
was determined that 11 patients with EE would need to
be treated with esomeprazole to prevent one treatment
failure that otherwise may occur with lansoprazole
regardless of the baseline grade of EE. As the severity of
disease increased (LA Grade C or D), the NNT to prevent
one relapse that may otherwise have occurred with lan-
soprazole decreased to 6. CONCLUSIONS: For patients
with more severe disease, the NNT was lower, indicating
a greater likelihood of therapeutic success with esome-
prazole versus lansoprazole. This evidence supports
esomeprazole as an effective treatment for maintenance
of remission and prevention of treatment failure in gas-
troesophageal reﬂux disease patients with EE.
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